Seeking Alpha

Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to...

Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.
Comments (3)
  • zorro2828
    , contributor
    Comments (602) | Send Message
     
    What's up with the Biotech's? CELG and GILD got hammered again.. has the whole market turned here and this is the time to bail?
    5 Jun 2013, 04:18 PM Reply Like
  • monumentalgains
    , contributor
    Comments (227) | Send Message
     
    good question, esp after they get FDA approval and still don't rally!
    5 Jun 2013, 06:16 PM Reply Like
  • zorro2828
    , contributor
    Comments (602) | Send Message
     
    Now, even with the FDA Approval and positive futures, the stock is bare moving ... is this a pure sector rotation or just the beginning of the 10 - 15% sell off?
    6 Jun 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector